At the news
? BULLISHIMPACT 7/10 8-K filed May 12, 2026 at 08:00 ET
MacroGenics entered into a definitive agreement to sell its GMP manufacturing operations (CDMO business) to Bora Pharmaceuticals for a $122.5 million upfront cash payment, subject to customary closing adjustments and up to $5 million in contingent milestones. The transaction, expected to close in Q3 2026, provides non-dilutive capital to fund the company's R&D pipeline while retaining manufacturing access via a supply agreement.
- Base purchase price of $122.5 million in cash at closing, subject to working capital and indebtedness adjustments.
- Up to $5 million in additional contingent payments based on manufacturing milestones through 2028.
- Transaction includes transfer of the Rockville, MD manufacturing facility (11,000L capacity) and Frederick, MD warehouse.
- Approximately 140 MacroGenics employees expected to be hired by Bora.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access